The use of sulfonamide derivatives in the treatment of trypanosomatid parasites including trypanosoma cruzi, trypanosoma brucei, and leishmania ssp

Página do item simplificado
dc.contributor.authorScarim, Cauê B. [UNESP]
dc.contributor.authorChelucci, Rafael C. [UNESP]
dc.contributor.authorDos Santos, Jean L. [UNESP]
dc.contributor.authorChin, Chung M. [UNESP]
dc.contributor.institutionUniversidade Estadual Paulista (Unesp)
dc.date.accessioned2020-12-12T01:13:16Z
dc.date.available2020-12-12T01:13:16Z
dc.date.issued2020-01-01
dc.description.abstractMore than 10 million people around the world are afflicted by Neglected Tropical Diseases, such as Chagas Disease, Human African Trypanosomiasis, and Leishmania. These diseases mostly occur in undeveloped countries that suffer from a lack of economic incentive, research, and policy for new compound development. Sulfonamide moieties are effective scaffolds present in several compounds that are determinants to treat various diseases, principally neglected tropical diseases. This review article examines the contribution of these scaffolds in medicinal chemistry in the last five years, focusing on three trypanosomatid parasites: Trypanosoma cruzi, Trypanosoma brucei, and Leishmania ssp. We also present perspectives for their use in drug designs in an effort to contribute to new drug development. In addition, we consider the physicochemical parameters, whose molecules all presented according to Lipinski's rule. The correlation between the selective index and LogP was evaluated, showing that sulfonamide derivatives can act differently against each trypanosomatid parasite. Moreover, the approaches of novel drugs and technologies are very important for the eventual drug discovery against trypanosomatid diseases.en
dc.description.affiliationSão Paulo State University (UNESP) School of Pharmaceutical Sciences
dc.description.affiliationUnespSão Paulo State University (UNESP) School of Pharmaceutical Sciences
dc.description.sponsorshipUniversidade Estadual Paulista
dc.description.sponsorshipCoordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
dc.description.sponsorshipFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.description.sponsorshipIdCAPES: 001
dc.description.sponsorshipIdFAPESP: 2016/10847-9
dc.format.extent24-38
dc.identifierhttp://dx.doi.org/10.2174/1573406415666190620141109
dc.identifier.citationMedicinal Chemistry, v. 16, n. 1, p. 24-38, 2020.
dc.identifier.doi10.2174/1573406415666190620141109
dc.identifier.issn1875-6638
dc.identifier.issn1573-4064
dc.identifier.lattes9734333607975413
dc.identifier.orcid0000-0003-4141-0455
dc.identifier.scopus2-s2.0-85078522046
dc.identifier.urihttp://hdl.handle.net/11449/198453
dc.language.isoeng
dc.relation.ispartofMedicinal Chemistry
dc.sourceScopus
dc.subjectChagas disease
dc.subjectHuman African Trypanosomiasis (HAT)
dc.subjectLeishmania
dc.subjectNew compounds
dc.subjectSulfonamides
dc.subjectTropical Diseases
dc.titleThe use of sulfonamide derivatives in the treatment of trypanosomatid parasites including trypanosoma cruzi, trypanosoma brucei, and leishmania sspen
dc.typeResenha
unesp.author.lattes9734333607975413[4]
unesp.author.orcid0000-0003-4141-0455[4]

Arquivos

Coleções

Artigos